Romain Rouet

Romain Rouet

Auto-generated profile, based on publicly available information

Romain Rouet

Garvan Institute of Medical Research

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2018 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
MZMahdi Zeraati
Mahdi Zeraati
DLDavid B. Langley
David B. Langley
PSPeter Schofield
Peter Schofield
AMAaron L. Moye
Aaron L. Moye
RRRomain Rouet
Romain Rouet
DCDaniel Christ
Daniel Christ

8 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMiguel Moreno-mateos
Miguel Moreno-mateos
JFJuan P. Fernandez
Juan P. Fernandez
RRRomain Rouet
Romain Rouet
CVCharles E. Vejnar
Charles E. Vejnar
MLMaura A. Lane
Maura A. Lane
AGAntonio J. Giraldez
Antonio J. Giraldez
Cpf1 is a novel class of CRISPR-Cas DNA endonucleases, with a wide range of activity across different eukaryotic systems. Yet, the underlying determinants of this variability are poorly understood. Here, we demonstrate that LbCpf1, but not AsCpf1, ribonucleoprotein complexes allow efficient mutagenesis in zebrafish and Xenopus. We show that temperature modulates Cpf1 activity by controlling its ability to access genomic DNA. This effect is stronger on AsCpf1, explaining its lower efficiency in ectothermic organisms. We capitalize on this property to show that temporal control of the temperature allows post-translational modulation of Cpf1-mediated genome editing. Finally, we determine that LbCpf1 significantly increases homology-directed repair in zebrafish, improving current approaches for targeted DNA integration in the genome. Together, we provide a molecular understanding of Cpf1 activity in vivo and establish Cpf1 as an efficient and inducible genome engineering tool across ectothermic species.

12 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CVClaire Vennin
Claire Vennin
PMPauline Mélénec
Pauline Mélénec
RRRomain Rouet
Romain Rouet
Max NobisMax Nobis
Max Nobis
ACAurélie S. Cazet
Aurélie S. Cazet
PTPaul Timpson
Paul Timpson
Heterogeneous subtypes of cancer-associated fibroblasts (CAFs) coexist within pancreatic cancer tissues and can both promote and restrain disease progression. Here, we interrogate how cancer cells harboring distinct alterations in p53 manipulate CAFs. We reveal the existence of a p53-driven hierarchy, where cancer cells with a gain-of-function (GOF) mutant p53 educate a dominant population of CAFs that establish a pro-metastatic environment for GOF and null p53 cancer cells alike. We also demonstrate that CAFs educated by null p53 cancer cells may be reprogrammed by either GOF mutant p53 cells or their CAFs. We identify perlecan as a key component of this pro-metastatic environment. Using intravital imaging, we observe that these dominant CAFs delay cancer cell response to chemotherapy. Lastly, we reveal that depleting perlecan in the stroma combined with chemotherapy prolongs mouse survival, supporting it as a potential target for anti-stromal therapies in pancreatic cancer.

12 May 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ZSZahra Sabouri
Zahra Sabouri
PSPeter Schofield
Peter Schofield
KHKeisuke Horikawa
Keisuke Horikawa
ESEmily Spierings
Emily Spierings
DKDavid Kipling
David Kipling
CGChristopher C. Goodnow
Christopher C. Goodnow
The best-understood mechanisms for achieving antibody self/non-self discrimination discard self-reactive antibodies before they can be tested for binding microbial antigens, potentially creating holes in the repertoire. Here we provide evidence for a complementary mechanism: retaining autoantibodies in the repertoire displayed as low levels of IgM and high IgD on anergic B cells, masking a varying proportion of autoantibody-binding sites with carbohydrates, and removing their self-reactivity by somatic hypermutation and selection in germinal centers (GCs). Analysis of human antibody sequences by deep sequencing of isotype-switched memory B cells or in IgG antibodies elicited against allogeneic RhD+ erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of anergic IgMlow IgD+ IGHV4-34+ B cells and removal of cold agglutinin self-reactivity by hypermutation, often accompanied by mutations that inactivated an N-linked glycosylation sequon in complementarity-determining region 2 (CDR2). In a Hy10 antibody transgenic model where anergic B cells respond to a biophysically defined lysozyme epitope displayed on both foreign and self-antigens, cell transfers revealed that anergic IgMlow IgD+ B cells form twice as many GC progeny as naïve IgMhi IgD+ counterparts. Their GC progeny were rapidly selected for CDR2 mutations that blocked 72% of antigen-binding sites with N-linked glycan, decreased affinity 100-fold, and then cleared the binding sites of blocking glycan. These results provide evidence for a mechanism to acquire self/non-self discrimination by somatic mutation away from self-reactivity, and reveal how varying the efficiency of N-glycosylation provides a mechanism to modulate antibody avidity. Significance Antibodies are selected to bind microbial but not self-antigens, because binding to self would compete with binding microbes, shorten antibody half-life, and cause autoimmunity. Self-tolerance is actively acquired in part by discarding self-binding antibodies before the body is exposed to a microbe or vaccine. The experiments here provide evidence of an opposite mechanism, allowing antibodies that initially bind both foreign and self-antigens to acquire self/non-self discrimination during the course of an immune response through somatic hypermutation away from self-reactivity. In addition to selection for lower-affinity binding to self, antibody variants were selected with fewer binding sites available to bind self-antigen because most were occupied by N-linked carbohydrate, possibly explaining the frequent occurrence of N-linked glycosylation of antibody variable domains.

27 June 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KDKip Dudgeon
Kip Dudgeon
RRRomain Rouet
Romain Rouet
IKIris Kokmeijer
Iris Kokmeijer
PSPeter Schofield
Peter Schofield
JSJessica Stolp
Jessica Stolp
DCDaniel Christ
Daniel Christ
The availability of stable human antibody reagents would be of considerable advantage for research, diagnostic, and therapeutic applications. Unfortunately, antibody variable heavy and light domains (VHand VL) that mediate the interaction with antigen have the propensity to aggregate. Increasing their aggregation resistance in a general manner has proven to be a difficult and persistent problem, due to the high level of sequence diversity observed in human variable domains and the requirement to maintain antigen binding. Here we outline such an approach. By using phage display we identified specific positions that clustered in the antigen binding site (28, 30–33, 35 in VHand 24, 49–53, 56 in VL). Introduction of aspartate or glutamate at these positions endowed superior biophysical properties (non-aggregating, well-expressed, and heat-refoldable) onto domains derived from common human germline families (VH3 and Vκ1). The effects of the mutations were highly positional and independent of sequence diversity at other positions. Moreover, crystal structures of mutant VHand VLdomains revealed a surprising degree of structural conservation, indicating compatibility with VH/VLpairing and antigen binding. This allowed the retrofitting of existing binders, as highlighted by the development of robust high affinity antibody fragments derived from the breast cancer therapeutic Herceptin. Our results provide a general strategy for the generation of human antibody variable domains with increased aggregation resistance.

1 January 2011
Verified
Book Chapter
Closed access
DLD. Lowe
D. Lowe
KDK. Dudgeon
K. Dudgeon
RRR. Rouet
R. Rouet
PSP. Schofield
P. Schofield
LJL. Jermutus
L. Jermutus
DCD. Christ
D. Christ